Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;40(8):3395-3409.
doi: 10.1007/s12325-023-02567-1. Epub 2023 Jun 16.

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review

Hanna Kwiendacz  1 , Katarzyna Nabrdalik  2 , Leszek Czupryniak  3 , Tomasz Klupa  4 , Maciej Małecki  4 , Małgorzata Myśliwiec  5 , Krzysztof Strojek  6 , Janusz Gumprecht  2
Affiliations
Review

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review

Hanna Kwiendacz et al. Adv Ther. 2023 Aug.

Abstract

iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide used in the treatment of type 2 diabetes. iGlarLixi has proven clinical benefits in terms of glycemia, weight control, and safety, defined by the risk of hypoglycemia. It simultaneously targets many pathophysiologic abnormalities which are at the root of type 2 diabetes and thus presents a complementary mode of action. Finally, it may also address diabetes treatment burden, and, by decreasing the complexity of treatment, it may improve patient adherence and persistence and fight against clinical inertia. This article reviews the results of major randomized controlled trials in people with type 2 diabetes that compared iGlarLixi to other therapeutic regimens, representing different intensification strategies, such as basal supported oral therapy, oral antidiabetic drugs, and a combination of the latter with glucagon-like peptide 1 receptor agonists. Moreover, as a supplement to randomized trials, data from real-world evidence have also been included.

Keywords: Diabetes mellitus; Fixed-ratio combination; Insulin glargine; LixiLan-G; LixiLan-L; LixiLan-O; Lixisenatide; SoliMix.

PubMed Disclaimer

Conflict of interest statement

Hanna Kwiendacz received remunerations/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, and Novo Nordisk. Leszek Czupryniak, Janusz Gumprecht, Tomasz Klupa, Maciej Małecki, Małgorzata Myśliwiec, Katarzyna Nabrdalik, and Krzysztof Strojek received remunerations/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Bioton, Polfa Tarchomin, Servier, Astra-Zeneca, Boehringer-Ingelheim, Medtronic, Roche, and Abbott.

Figures

Fig. 1
Fig. 1
HbA1c value changes from baseline till the end of the trials during the treatment with iGlarLixi, iGlar, BIAsp30, and Lixi on the basis of the LixiLan-O, LixiLan-G, Solimix, and LixiLan-L studies
Fig. 2
Fig. 2
Proportion of patients achieving HbA1c < 7.0% from baseline till the end of the trials during the treatment with iGlarLixi, iGlar, BIAsp30, and Lixi on the basis of the LixiLan-O, LixiLan-G, Solimix, and LixiLan-L studies
Fig. 3
Fig. 3
Mean body weight changes from baseline till the end of the trials during the treatment with iGlarLixi, iGlar, BIAsp30, and Lixi on the basis of the LixiLan-O, LixiLan-G, Solimix, and LixiLan-L studies
Fig. 4
Fig. 4
Percentage of patients with symptomatic hypoglycemia caused by the treatment with iGlarLixi, iGlar, BIAsp30, and Lixi during the LixiLan-O, LixiLan-G, Solimix, and LixiLan-L studies
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Diabetes Federation. IDF diabetes atlas, 10th edn. Brussels, Belgium: 2021. https://www.diabetesatlas.org. Accessed 20 April 2023
    1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2022;45(11):2753–2786. - PMC - PubMed
    1. Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–2237. - PMC - PubMed
    1. Prattichizzo F, La Sala L, Ceriello A. Two drugs are better than one to start T2DM therapy. Nat Rev Endocrinol. 2020;16(1):15–16. - PubMed
    1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. - PMC - PubMed